The neuropeptide oxytocin has emerged as a promising pharmacotherapy for methamphetamine (METH) addiction, and clinical trials of intranasal oxytocin are underway. However, there is debate as to how peripherally administered oxytocin alters brain signaling to modulate addiction processes. Interestingly, there is evidence for functional interactions between peripheral oxytocin administration and the vagus nerve. Therefore, this study investigated whether the effects of peripherally administered oxytocin require vagal signaling to reduce METH self-administration and reinstatement of METH-seeking behaviours.
Introduction
Abuse of the addictive psychostimulant methamphetamine (METH) is associated with numerous psychosocial and physical risks 1 . Current psychosocial interventions for METH use disorder are not widely available and are minimally effective 2 , and despite significant advances in understanding the neurobiology of METH addiction, no effective pharmacotherapies have been developed 3, 4 . As the pharmacological agents based on these advances progress through clinical trials and continue to produce largely negative findings 5 , there is an urgent need to develop new pharmacotherapies.
The neuropeptide oxytocin is a promising novel therapy for METH addiction [6] [7] [8] [9] [10] . Preclinical studies have shown that peripherally administered oxytocin can suppress METH selfadministration 11 , and relapse-like behavior elicited by METH-cues [12] [13] [14] or by METH reexposure [15] [16] [17] . When administered chronically during abstinence from METH, oxytocin also protects against cue-and METH-induced relapse in male and female rats 18 . Clinical research also indicates efficacy of intranasally delivered oxytocin in reducing alcohol and marijuana cravings [19] [20] [21] . A synthesis of these preclinical and clinical findings has laid the groundwork for the first clinical trial using intranasal oxytocin in METH-dependent users 22 (NCT02881177).
However, intranasal oxytocin treatment has not always been effective (see 23 for review), which raises concerns as to whether intranasal administration in humans will recapitulate the effects of peripheral administration in rodents.
Peripheral administration of oxytocin evokes powerful anti-addiction effects, however, it is unclear how the large peptide accesses the brain following peripheral dosing to modulate neural circuits which control addiction processes 24 . Indeed, as little as 0.002-0.005% of subcutaneously or intranasally administered oxytocin can be measured in the brain 23, 25 , while supraphysiologic concentrations of circulating oxytocin are measured following treatment with these peripheral doses 26 . As oxytocin receptors are expressed widely throughout the body 26 , it is possible that peripherally administered oxytocin may signal to the brain via a peripherally mediated mechanism.
The vagus nerve bidirectionally conveys information between the brain and the peripheral organs, with up to 80% of afferent fibers signaling to the brain 27 . The primary recipient of these vagal afferents is the nucleus of the solitary tract (NTS), which has noradrenergic projections to various brain regions involved in addiction 28 , as well as projections to the paraventricular (PVN) and supraoptic (SON) nuclei of the hypothalamus which appose oxytocin-secreting neurons 29 .
This ascending vagal pathway is therefore well positioned to regulate the function of the endogenous oxytocin system, as stimulation of vagal afferents elevates circulating oxytocin levels 30 and increases neuronal activity in the NTS and PVN 31 . Importantly, abdominal vagal fibers express oxytocin receptors 32 , as well as vasopressin V1A receptors 33 which oxytocin also acts on to reduce addictive behaviours 15 , and are excited by oxytocin in ex vivo preparations 32 .
Together, these studies provide a framework in which the vagus nerve is a gateway for peripherally administered oxytocin to signal to the brain to regulate behaviour.
Stimulation of the vagus nerve is being investigated as a therapy for a variety of psychiatric conditions 34 which oxytocin also has efficacy for treating, including depression 35,36 , anxiety 37,38 , and post-traumatic stress disorder 39, 40 . Further, vagus nerve stimulation (VNS) has preclinical efficacy for reducing addiction-like behaviours. Specifically, chronic VNS during daily extinction sessions from heroin or cocaine self-administration reduced relapse-like behaviours, operant behaviour, only a single oxytocin dose was tested compared with vehicle. The lower dose was chosen due to its vagal-dependent effects on METH self-administration. Rats then underwent three METH-primed reinstatement tests, in which rats received saline or oxytocin (0.3, 1.0 mg/kg IP) 30 minutes prior to a METH injection (1 mg/kg IP), and then were placed immediately into the chamber under extinction conditions. Each reinstatement test was separated by 2-3 extinction days. Rats did not proceed to the next test day until they reached extinction criteria (<10 active pokes). Treatments were counterbalanced within each reinstatement type.
Functional test of vagotomy
For the week following reinstatement tests, food was removed from home cages (16h deprivation from 10pm-2pm 46 ), and rats were trained to consume their food in a metabolic chamber (1h/day at 2-3pm). Food was returned to their home cage for another 7 hours. Once consumption was stable across 2 days, rats were tested for their intake following treatment with saline or CCK-8 (4µg/kg IP; Abcam, ab120209) 30 minutes prior to being placed in the chamber. Food consumed after 1h was recorded, and effects of CCK-8 on intake is expressed in text as percent reduction of intake compared to the day prior (percentage reduction of intake = -100(intake day prior -intake following CCK-8)/intake day prior).
Statistical Analysis
We used factorial analyses of variance and t tests using SPSS (Version 25, General Linear Model Procedure). Significant main and interaction effects (p<0.05) were followed by post-hoc tests (Fisher's least significant difference). Significant effects crucial for data interpretation are indicated in figures, with the remainder in Supplemental Results. For self-administration data, the analysis was performed on METH infusions earned. For reinstatement data, analysis was performed on active nose pokes. The first 30-minutes of sessions were analysed, as the effects of oxytocin dissipate after this time (Supplemental Figure 2) .
RESULTS

Excluded Animals
One female sham rat lost catheter patency during self-administration, so was excluded. During extinction, one female sham rat was euthanized due to poor health. Final sample sizes were n=10 for male sham, male SDV, and female SDV, and n=8 for female sham.
Acquisition of methamphetamine self-administration
All rats acquired METH self-administration (>10 infusions/session; Figure 1 ). Total METH intake did not differ based on a sex×surgery interaction (F(1,34)=0.024, p=0.899), sex (F(1,34)=0.059, p=0.811) or surgery (F(1,34)=1.005, p=0.271).
Vagotomy attenuated oxytocin inhibition of methamphetamine self-administration in both sexes
Self-administered METH on test days was normalized to intake on the prior day (percent reduction; Figure 2 ). There was no interaction of sex×surgery×dose on METH intake (F(1,34)=0.295, p=0.591), however, there was a significant surgery×dose interaction (F(2,68)=8.267, p=0.001). As three levels of dose were included, simple 2×2 interactions were analysed between surgery levels, and within pairs of levels of dose. This revealed significant surgery×dose interactions when comparing 0 vs 0.3 mg/kg (F(1,34)=11.695, p=0.002) and 0 vs 1 mg/kg (F(1,34)=5.372, p=0.027), whereby oxytocin treatment suppressed METH intake less in SDV rats than in sham operated rats. Interestingly, there was a significant interaction of surgery×dose when comparing 0.3 vs 1 mg/kg (F(1,34)=5.035, p=0.031), as SDV attenuated the inhibitory effect of oxytocin on METH intake more so at 0.3 than at 1 mg/kg. There was also a significant interaction of sex×dose on infusions when comparing 0 vs 1 mg/kg (F(1,34)=9.738, p=0.004), but not 0 vs 0.3 (F(1,34)=1.304, p=0.261), or 0.3 vs 1 mg/kg (F(1,34)=3.456, p=0.072), indicating that 1 mg/kg oxytocin was more effective at reducing METH intake in females. Simple contrasts comparing METH infusions between individual levels of dose, sex, and surgery are depicted in Figure 2 , and in Supplemental Tables 1-5 .
Extinction of methamphetamine self-administration
Rats decreased their active nose-pokes and locomotor activity over the 14 days of extinction (for all groups, Day 1 vs 14: p<0.05), and all rats met standard criteria of <10 active nose-pokes before proceeding to reinstatement tests (Supplemental Figure 1 ).
Vagotomy attenuated oxytocin inhibition of cue-induced reinstatement in males but not females
Assessing active nose pokes during cue-induced reinstatement, there were no interactions of sex×surgery×dose (F1,33)=0.975, p=0.331; Figure 3 ) or sex×surgery (F(1,33)=1.115, p=0.299), and no main effects of surgery (F(1, 33)=0.062, p=0.805) or sex (F(1, 33)=1.297, p=0.263).
There was a significant main effect of oxytocin dose on active nose-pokes (F(1,33)=39.630, p<0.001), and significant interactions of dose×sex (F(1,33)=7.480, p=0.010) and dose×surgery (F(1,33)=5.711, p=0.023), whereby the inhibitory effects of oxytocin on cue-induced reinstatement were more potent in females, and were attenuated by SDV. To best assess the effects of SDV and oxytocin within each sex, active nose-pokes following 0.3 mg/kg oxytocin were normalised to the vehicle session. This showed that oxytocin suppressed active nose-pokes significantly less in SDV than sham males (t(17)=2.208, p=0.041), while SDV and sham females were not significantly different (t(16)=0.887, p=0.388; Fig 5d) . Simple contrasts comparing active nose-pokes and locomotor activity between individual levels of dose, sex, and surgery are depicted in figure 3, and in Supplemental Tables 6-9 .
Vagotomy attenuated oxytocin inhibition of methamphetamine-primed reinstatement in males but not females
There were significant main effects of sex (F(1,33)=4.658, p=0.038) and dose (F(2,33)=20.235, p<0.001), but not SDV (F(1,33)=0.011, p=0.917) on active nose-pokes made during METHprimed reinstatement (Figure 4 ). There was a significant surgery×dose interaction (F(2,66)=3.309, p=0.043), and as three levels of dose were included, 2×2 interactions were conducted between surgery levels, and within pairs of levels of dose for males and females separately. For males, this revealed a significant surgery×dose interaction when comparing 0 vs In further support of these interactions, when the effects of oxytocin on active nose-pokes were normalised to the vehicle session, SDV males nose-poked significantly more than shams at both 0.3 mg/kg (p=0.039) and 1.0 mg/kg doses (p=0.047), while SDV females were not significantly different to sham females at either dose (p=0.264 and 0.315 respectively). Simple contrasts comparing active nose-pokes and locomotor activity between individual levels of dose, sex, and surgery are depicted in figure 4, and in Supplemental Tables 10-13 .
Vagotomy was functionally confirmed by cholecystokinine-8 suppression of food consumption
There was a significant main effect of surgery (F(1,33)=6.037, p=0.019; Figure 7 ), whereby SDV rats had lower body weight than sham rats, and a significant interaction of surgery×week (F(8,272)=6.524, p<0.001), indicating the weight differences dissipated over time. There was no sex×surgery interaction for weight (F(1,33)=0.099, p=0.755). CCK-8 treatment reduced feeding by at least 35% in all sham rats, whereas no SDV rats had a reduction of intake greater than 24%.
There was a significant effect of surgery (F(1,33)=37.902, p<0.001), whereby feeding was reduced in sham but not SDV rats. There was no interaction of sex×surgery (F(1,33)=1.486, p=0.234), and no main effect of sex (F(1,33)=0.516, p=0.478), on reduction of food intake following CCK-8 treatment.
Discussion
Here we present the novel finding that the inhibitory effect of peripherally administered oxytocin on METH addiction-like behaviours depends on subdiaphragmatic vagal signaling. Specifically, the effect of a low dose of oxytocin to inhibit METH self-administration were absent in male and female rats which had undergone subdiaphragmatic vagotomy, yet persisted in sham controls.
Conversely, the inhibitory effect of a higher dose of oxytocin on METH intake were only partially attenuated by vagotomy in males, and were vagal-independent in females. After a period of extinction, vagotomy reduced the inhibitory effect of oxytocin treatment on cueinduced and METH-primed reinstatement to METH-seeking behaviours in males, but not females. These data provide clear evidence for a role of vagal signaling in the anti-addiction effect of oxytocin treatment and suggest that sex-dependent oxytocin-vagal mechanisms emerge following METH withdrawal.
Oxytocin administered at 0.3 mg/kg potently reduced METH self-administration, which was almost entirely prevented by SDV in both sexes. However, at the 1 mg/kg oxytocin dose, this vagal dependency was less pronounced. Sham females were also more sensitive to this higher dose compared to sham males. One explanation for this dose-dependent involvement of the vagus nerve for the effect of oxytocin is increased penetration of the blood-brain barrier at higher doses of oxytocin 47 . Recent studies in oxytocin-null mice, which cannot produce oxytocin, demonstrate that peripheral oxytocin injection results in a substantial increase in brain oxytocin levels 48, 49 . As such, it is possible that the brain concentrations of oxytocin achieved by the low dose are insufficient to inhibit METH self-administration in SDV rats. Rather, suppression of METH intake by this low dose in shams may be achieved through stimulation of an ascending vagal pathway to the brain. In contrast, the high oxytocin dose may result in brain concentrations of oxytocin which are sufficient to inhibit METH seeking, despite the lack of vagal signaling.
Both sexes were similar with regard to the vagal-dependent effects of IP oxytocin on suppressing METH-intake. These data clearly implicate the vagus nerve as a crucial target for IP oxytocin in reducing METH intake, and yet are not inconsistent with observations of behaviorally relevant blood-brain passage of peripherally administered oxytocin, particularly at higher doses.
Following extinction of drug-seeking and withdrawal from METH, the role of the vagus nerve in mediating the effects of oxytocin on METH behaviours appears to be more complex. In males, 0.3 mg/kg oxytocin reduced cue-induced reinstatement, which was partially attenuated by vagotomy, and both the effect of oxytocin and the interference by SDV seemed independent of a locomotor effect. For METH-primed reinstatement, 0.3 and 1.0 mg/kg oxytocin potently reduced METH-primed reinstatement in shams but had no effect in SDV males, which was also separable from the effect of oxytocin on METH-induced locomotor activity. These results indicate that despite undergoing extinction and withdrawal, the vagus nerve mediates the inhibitory effects of peripheral oxytocin treatment on METH-seeking behaviours in males.
In females, 0.3 mg/kg oxytocin potently reduced cue-induced reinstatement, and 0.3 and 1.0 mg/kg oxytocin reduced METH-primed reinstatement, in both sham and SDV females. These effects of oxytocin on reinstatement, and interference by SDV are largely independent of an effect on locomotor activity, although the 1 mg/kg dose attenuated METH-induced locomotor activity less in SDV than in sham females. Surprisingly, the female reinstatement data is in stark contrast to the almost entire vagal dependency of the effects of 0.3 mg/kg oxytocin on METH self-administration, and slight mediation of the 1.0 mg/kg dose by SDV in these same rats. It is also in contrast to the enduring vagal dependency of oxytocin's effects seen in male SDV rats.
The divergent interactions of SDV, oxytocin, and sex between self-administration and reinstatement are challenging to interpret, due to the lack of female subjects included in oxytocin, METH, and vagal research. However, there are several possible explanations for the present sex differences. Firstly, there is evidence that expression of oxytocin receptors is altered by chronic METH self-administration and extinction in male rodents 50,51 . As females and males have non-identical patterns of oxytocin receptor expression 52 it is possible that METH-and extinction-induced plasticity of oxytocin receptors may result in an augmented sensitivity to the concentration of IP oxytocin which crosses the BBB in SDV females. Alternatively, METH selfadministration causes BBB injury 53 , which may result in greater penetration of IP oxytocin into the brain. Indeed, the mechanism by which oxytocin is transported into the brain has recently been identified 48 , and this system may be affected by METH exposure 54 . However, the effect of METH exposure and withdrawal on oxytocin receptors or BBB integrity has mostly been studied in male subjects, so it is unclear whether there are sex-dependent effects of METH on either of these systems. Lastly, the effects of VNS in addiction models have also only been explored in males 41,42 , rendering it unknown whether VNS can achieve similar anti-addiction effects in females.
It is unlikely that the altered vagal dependency of oxytocin treatment observed in females following extinction could be due to regeneration of vagal nerve endings over the 3 weeks separating self-administration and reinstatement tests. Vagal regeneration can occur after ~5 months post-SDV in rats, however even after this time it is estimated that only ~7-39% of fibres regenerate 55 . Given the 3-week timespan separating our vagal-dependent and vagal-independent effects of oxytocin in females, regeneration is unlikely to explain our data. Indeed, if this effect was due to vagal regeneration, then the enduring vagal dependency of oxytocin in males would suggest profound sex differences in vagal regrowth. We are not aware of any literature to support sex-dependent regeneration of peripheral nerves to this extent. Regardless, functional vagotomy was confirmed in both sexes after reinstatement tests by administering the satiety-signaling peptide CCK-8, which inhibits feeding through subdiaphragmatic vagal signaling 56 . This test at the very least confirms that vagal afferents sensitive to CCK-8 were non-functional. As oxytocin has been shown to stimulate a similar population of nodose ganglion neurons as CCK-8 32 , we can be confident that the sex-dependent mediation of oxytocin treatment on reinstatement by SDV is not due to vagal regeneration. Alternatively, high levels of peripherally circulating oxytocin could reach the nodose ganglion, activating the cell bodies of the vagi which project to the NTS. Such a vagal-or nodosedependent effect has been shown in the transmission of peripheral immune signals to the brain 65 , and may explain our findings.
These findings have implications for the design and interpretation of clinical studies, and for the applicability of oxytocin as a pharmacotherapy for METH-use disorders. Firstly, it is crucial that sex is included as a biological variable. Currently, the only registered trial investigating the efficacy of oxytocin on METH addiction outcomes is in treatment seeking HIV-positive males 22 .
As such, it should not be presumed that the results of this trial will inform the suitability of oxytocin as a therapy for females, who according to our findings, and others 43 , may be more sensitive to oxytocin treatment, and may have non-identical peripheral-to-central signaling pathways for oxytocin. Furthermore, as the vagal-dependent effects of peripherally administered oxytocin may change throughout withdrawal, oxytocin should be explored at timepoints encompassing current use, and into abstinence. Lastly, as intranasal delivery of oxytocin in the clinic gains both momentum and controversy 23 , the differences between intranasal and IP administration must be considered. Unlike IP, IN oxytocin does not increase activity in the mouse NTS 66 , which may preclude the therapeutic benefits of stimulating this vagal-mediated pathway. Furthermore, IP oxytocin produces substantially higher plasma levels of oxytocin than In conclusion, we discovered that the well documented preclinical effects of peripherally administered oxytocin in reducing METH self-administration and reinstatement to METHseeking behaviours is largely dependent upon the subdiaphragmatic vagus nerve. Sex differences in this vagal dependency of oxytocin's effects emerged after withdrawal, which has implications for the clinical utility of oxytocin. Lastly, the growing momentum towards intranasal delivery of oxytocin to bypass the blood-brain barrier should be considered in light of these findings, which indicate that in rats, a considerable amount of the therapeutic effects of oxytocin for treating METH addiction is mediated by the vagus nerve. As such, drugs or implants which target oxytocin-sensitive vagal pathways may prove to be valuable therapies for METH addiction. 
